Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antiplatelet treatment in stable coronary artery disease.

× No keyword cloud information.

20 in total

Review 1. Aspirin.

Authors: E H Awtry; J Loscalzo
Journal: Circulation Date: 2000-03-14 Impact factor: 29.690

Review 2. Platelets.

Authors: J N George
Journal: Lancet Date: 2000-04-29 Impact factor: 79.321

3. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?

Authors: Martin J Quinn; Edward F Plow; Eric J Topol
Journal: Circulation Date: 2002-07-16 Impact factor: 29.690

Review 4. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.

Authors: D A Vorchheimer; J J Badimon; V Fuster
Journal: JAMA Date: 1999-04-21 Impact factor: 56.272

Review 5. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review.

Authors: Koon K Teo; Salim Yusuf; Marc Pfeffer; Christian Torp-Pedersen; Lars Kober; Alistair Hall; Janice Pogue; Roberto Latini; Rory Collins
Journal: Lancet Date: 2002-10-05 Impact factor: 79.321

6. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events.

Authors: W W O'Neill; P Serruys; M Knudtson; G A van Es; G C Timmis; C van der Zwaan; J Kleiman; J Gong; E B Roecker; R Dreiling; J Alexander; R Anders
Journal: N Engl J Med Date: 2000-05-04 Impact factor: 91.245

7. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Authors:
Journal: BMJ Date: 2002-01-12

8. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes.

Authors:
Journal: Lancet Date: 2000-01-29 Impact factor: 79.321

9. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.

Authors: C P Cannon; C H McCabe; R G Wilcox; A Langer; A Caspi; P Berink; J Lopez-Sendon; J Toman; A Charlesworth; R J Anders; J C Alexander; A Skene; E Braunwald
Journal: Circulation Date: 2000-07-11 Impact factor: 29.690

3. Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis.

Authors: Xiaojun Zhuo; Bi Zhuo; Shenyu Ouyang; Pei Niu; Mou Xiao
Journal: BMC Pharmacol Toxicol Date: 2018-09-03 Impact factor: 2.483

3 in total

Antiplatelet treatment in stable coronary artery disease.